Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA
International journal of chronic obstructive pulmonary disease, Volume 13, 2018, Pages 2969-2984.
COPDbronchodilatorco-suspension delivery technologymuscarinic antagonistβ2-agonist
These results demonstrated the efficacy of GFF MDI in patients with moderate-to-very severe COPD. GFF MDI was well tolerated, with a safety profile commensurate with long-acting bronchodilators.
Full Text (Upload PDF)
PPT (Upload PPT)